Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2021 Feb 16;16(2):e0246963. doi: 10.1371/journal.pone.0246963

30-day mortality after hip fracture surgery: Influence of postoperative factors

Juan F Blanco 1,2, Carmen da Casa 2,*, Carmen Pablos-Hernández 2,3, Alfonso González-Ramírez 2,3, José Miguel Julián-Enríquez 1,2, Agustín Díaz-Álvarez 2,4
Editor: Osama Farouk5
PMCID: PMC7886122  PMID: 33592047

Abstract

Purpose

The 30-day mortality rate after hip fracture surgery has been considered as an indirect indicator of the quality of care. The aim of this work is to analyse preoperative and postoperative factors potentially related to early 30-day mortality in patients over 65 undergoing hip fracture surgery.

Methods

Prospective cohort study including all consecutive primary hip fracture patients over 65 admitted to Trauma and Orthopaedics department from January 1, 2018 to December 31, 2019. Bed-ridden, non- surgically treated patients, and high energy trauma or tumoral aetiology fractures were excluded. A total of 943 patients were eligible (attrition rate: 2.1%). Follow-up included 30-days after discharge. We noted the 30-day mortality after hip fracture surgery, analysing 130 potentially related variables including biodemographic, fracture-related, preoperative, and postoperative clinical factors. Qualitative variables were assessed by χ2, and quantitative variables by non-parametric tests. Odds ratio determined by binary logistic regression. We selected preventable candidate variables for multivariate risk assessment by logistic regression.

Results

A total of 923 patients were enrolled (mean age 86.22±6.8, 72.9% women). The 30-day mortality rate was 6.0%. We noted significant increased mortality on men (OR = 2.381[1.371–4.136], p = 0.002), ageing patients (ORyear = 1.073[1.025–1.122], p = 0.002), and longer time to surgery (ORday = 1.183[1.039–1146], p<0.001), on other 20 preoperative clinical variables, like lymphopenia (lymphocyte count <103/μl, OR = 1.842[1.063–3.191], p = 0.029), hypoalbuminemia (≤3.5g/dl, OR = 2.474[1.316–4.643], p = 0.005), and oral anticoagulant intake (OR = 2.499[1.415–4.415], p = 0.002), and on 25 postoperative clinical variables, like arrhythmia (OR = 13.937[6.263–31.017], p<0.001), respiratory insufficiency (OR = 7.002[3.947–12.419], p<0.001), hyperkalaemia (OR = 10.378[3.909–27.555], p<0.001), nutritional supply requirement (OR = 3.576[1.894–6.752], p = 0.021), or early arthroplasty dislocation (OR = 6.557[1.206–35.640], p = 0.029). We developed a predictive model for early mortality after hip fracture surgery based on postoperative factors with 96.0% sensitivity and 60.7% specificity (AUC = 0.863).

Conclusion

We revealed that not only preoperative, but also postoperative factors have a great impact after hip fracture surgery. The influence of post-operative factors on 30-day mortality has a logical basis, albeit so far they have not been identified or quantified before. Our results provide an advantageous picture of the 30-day mortality after hip fracture surgery.

Introduction

Treatment of hip fractures in the older population is a relevant part of the healthcare activity of trauma and orthopaedic services. In the last years, many factors have raised to improve the results of hip fracture treatment, like the early surgery rates or the establishment of healthcare multidisciplinary units, the so-called orthogeriatric units [1, 2]. Despite these improvements, mortality following a hip fracture is high [3]. The early mortality rate, defined as 30-day mortality rate after hospital discharge, has been considered as an indirect indicator of the quality of care [4]. It seems to be interesting to identify the more susceptible patients to early die and thereby increase the resources and efforts for their treatment. Many studies have looked into different factors that could be associated with early mortality after hip fracture [48]. Previous works show also differences in the results depending on the country where the study was carried out. These differences could, in part, also reflect differences in life-expectancy and healthcare systems [9]. The most frequently early mortality related factors include biodemographic factors, like age and gender, and clinical factors, like time to surgery or comorbidities [10]. Some recently developed models assessing early mortality after hip fracture showed limited application and no postoperative approach have been assessed [11, 12]. Although these factors could be less modifiable, knowing whether they can affect the early outcome would represent a great advantage for the older hip fracture patients’ management.

The aim of this work is to analyse which factors—not only preoperative, but also postoperative and in-hospital-derived factors—could be related to 30-day mortality in patients older than 65-years-old who underwent surgery following a hip fracture at the University Hospital of Salamanca, and therefore establish a predictive model for early mortality so it could help to improve the in-hospital healthcare to this group of patients.

Materials and methods

We design a prospective cohort study including all patients undergoing hip fracture surgery at the University Hospital of Salamanca from January 1st 2018 to December 31st 2019.

We included all patients over 65 with the main diagnosis of primary hip fracture. We excluded bed-ridden patients, non- surgically treated patients, and high energy trauma or tumoral aetiology fractures. In all cases, neuraxial anaesthesia was used [13]. A total of 943 patients were enrolled by signing informed consent, from whose clinical history we collected data for 130 variables. We performed on-site or telephonic 30-day follow up, noting down records for mortality. The attrition rate was 2.1%, leading a study population of 923 patients.

The study variables are grouped as biodemographic variables, like gender or place of residence; fracture-related variables, like the type of fracture or time to surgery; preoperative clinical variables, like comorbidities or admission laboratory data; and postoperative clinical variables, like surgical complications, medical complications, or walking ability at discharge.

Ethics approval

The whole study was conducted following the Declaration of Helsinki and previously approved by the ethics committee for clinical research (CEIm) of the University Hospital of Salamanca (code: PI202001418). All participants (or their relatives) have given their written informed consent to participate.

Statistics

Data collection was done using Microsoft® Office Access 2016 (Microsoft, Inc., Redmond, WA) and data analysis was done using IBM® SPSS Statics, version 25 (IBM, Inc., Armonk, NY).

Qualitative variables were analysed by contingency tables, and their statistical significance was assessed by χ2. Quantitative variables were analysed by mean, standard deviation, median, and range, and their statistical significance was assessed by non-parametric tests.

We performed a univariate risk assessment, estimating the odds ratio (OR) by binary logistic regression. For the multivariate analysis, we randomized patients at 50% to validate the results in half population. Seeking into previous analyses, we selected preventable candidate variables for multivariate risk assessment. We determined a predictive model for 30-days mortality, evaluated by logistic regression and ROC curve. We considered statistically significant p≤0.05 in all cases.

Results

A total of 923 patients were enrolled and completed the 30-day follow-up. We noted a 30-day mortality rate of 6.0%, including 3.4% of in-hospital mortality rate.

Table 1 shows descriptive data for all biodemographic and fracture-related factors analysed in the study.

Table 1. Frequencies of biodemographic and fracture-related variables.

Total population (n = 923) Survival (n = 868) 30-day mortality (n = 55) p-value
Biodemographic variables
Female gender 72.9% 74.1% 54.5% 0.002
Age (years) 86.22 ± 6.80 86.05 ± 6.79 88.93 ± 6.48 0.006
87 [65–103] 87 [65–103] 89 [73–100]
Older than 85-years-old 64.8% 64.2% 74.5% 0.118
Older than 90-years-old 32.4% 31.3% 49.1% 0.006
Rural municipality (<12,500 inhabitants) 48.2% 48.6% 41.8% 0.328
Institution-living (Nursing facility)
At admission 32.8% 33.0% 29.1% 0.550
At discharge 54.6% 54.4% 58.8% 0.612
Post-hospitalization 32.1% 31.8% 39.1% 0.458
Fracture-related variables
Left side 53.0% 53.20% 54.50% 0.849
Type of fracture 0.525
Subcapital 43.2% 43.0% 47.3%
Basicervical 4.7% 4.7% 3.6%
Pertrochanteric 45.8% 45.7% 47.3%
Subtrochanteric 6.3% 6.6% 1.7%
Intracapsular fracture 53.0% 52.3% 49.1% 0.644
Surgical intervention 0.482
Osteosynthesis 55.9% 56.0% 54.5%
Partial Hip Replacement 41.9% 41.7% 45.5%
Total Hip Replacement 2.2% 2.3% -
Time to surgery (days) 2.89 ± 2.57 2.80 ± 2.46 4.33 ±3.67 0.001
3 [0–23] 2 [0–23] 4 [0–20]
Delay <24 hours 18.5% 19.2% 7.3% 0.027
Delay <48 hours 36.1% 36.9% 23.6% 0.048

Frequencies are shown in percentages and quantitative variables are described by mean ± standard deviation and median [range]. Significant differences on survival and early mortality comparison are marked in bold.

Biodemographic variables

We noted a significantly higher rate of men in the early-mortality group (OR = 2.381 [1.371–4.136], p = 0.002), showing increasing proportion than the original population gender distribution. We also noted an increased risk for the 30-day mortality with the increasing age of patients (OR per year = 1.073 [1.025–1.122], p = 0.002), and a higher rate of patients over age 90, than patients under 90, in the 30-day mortality group (p = 0.006). We did not note significant differences regarding the place of residence or institution-living patients.

Fracture-related variables

We did not note significant differences in the type of diagnosis or type of surgical procedure. We noted significant differences in the increasing time to surgery (OR per day = 1.183 [1.039–1146], p<0.001), noting down the protective effect for patients treated in the first 24h (OR = 0.329 [0.117–0.924], p = 0.035).

The complete analysed descriptive data for all preoperative and postoperative factors analysed in the study are on S1 Table.

Preoperative clinical variables

Among the lab preoperative clinical variables analysed, we noted significant differences on the incidence of lymphopenia (lymphocyte count <103/μl, OR = 1.842 [1.063–3.191], p = 0.029) and the albumin admission level (OR per g/dl = 0.507 [0.268–0.959], p = 0.037), establishing the critical point at albumin admission level ≤3.5g/dl (OR = 2.474 [1.316–4.643], p = 0.005).

We also noted significant differences in patients presenting chronic cardiac insufficiency (OR = 3.560 [1.955–6.482], p<0.001), previous diagnosis of arrhythmia (OR = 2.523 [1.436–4.434], p = 0.001), and previous history of ischemic heart failure (OR = 1.980 [1.012–3.873], p = 0.046). We also noted significant differences in patients taking oral anticoagulants (OR = 2.499 [1.415–4.415], p = 0.002), accented in patients treated with acenocoumarol (OR = 2.499 [1.704–5.610], p<0.001). On the other hand, we observed a decreasing incidence of daily aspirin intake (≤100mg/day) on the early mortality group, although no statistical significance was achieved (OR = 0.527 [0.254–1.093], p = 0.085).

We noted significant differences in patients with chronic obstructive pulmonary disease (OR = 2.096 [1.019–4.314], p = 0.044), and patients with a previous history of lung cancer (OR = 5.403 [1.065–27.413], p = 0.023), but no for other types of malignancy.

We also noted significant differences on ASA grade (OR = 3.273 [1.944–5.512], p<0.001) and Charlson comorbidity index (OR = 1.236[0.070–1.428], p = 0.004/High comorbidity (≥3) OR = 1.969 [1.132–3.422], p = 0.016).

Postoperative clinical variables

Postoperative surgical complications

Considering the arthroplasty patients—hemiarthroplasty and total hip arthroplasty, n = 407 –, we noted significant differences on early dislocation incidence for the 30-day mortality (OR = 6.557 [1.206–35.640], p = 0.029).

Postoperative medical complications

We noted significant differences on many postoperative medical variables (OR = 4.050 [1.446–11.338], p = 0.008).

We noted significant differences on postoperative renal insufficiency (acute and flared-up, OR = 4.75 [2.446–9.205], p<0.001) and postoperative paralytic ileum (OR = 7.080 [1.77–28.174], p = 0.005).

We noted significant differences on cardiac complications (OR = 16.768 [9.052–31.062], p<0.001), including postsurgical arrhythmia (OR = 13.937 [6.263–31.017], p<0.001) and cardiac insufficiency (OR = 12.897 [6.525–25.488], p<0.001).

We also noted significant differences on respiratory complications (OR = 6.621 [3.769–11.631], p<0.001), including respiratory insufficiency (both acute and flared-up, OR = 7.002 [3.947–12.419], p<0.001) and upper respiratory infection (OR = 3.800 [1.499–9.635], p = 0.005).

We noted significant differences on sepsis (OR = 24.923 [4.075–152.436], p = 0.001), on postoperative nutritional supply requirement (OR = 3.576 [1.894–6.752], p = 0.021), and neurological complications (OR = 2.927 [1.629–5.258], p = 0.001), including postoperative delirium (OR = 2.565 [1.405–4.683], p = 0.002) and stroke (OR = 24.923 [4.075–152.436p<0.001).

We also noted statistical differences on metabolic ionic complications (OR = 3.287 [1.852–5.834], p<0.001), including sodium deregulation (OR = 2.929 [1.407–6.096], p = 0.004), hypernatremia (OR = 3.314 [1.092–10.056], p = 0.034) and hyponatremia (OR = 2.461 [0.997–6.076], p = 0.05), and potassium deregulation (OR = 5.238 [2.68–10.209], p<0.001), hyperkalaemia (OR = 10.378 [3.909–27.555], p<0.001) and hypokalaemia (OR = 2.934 [2.251–6.884], p = 0.013).

We also analysed in-hospital stay variables, noting a significant slight risk in the increasing length of stay (LOS) (OR per day = 1.091 [1.039–1.146], p = 0.001) and unveiling a protective factor for the walking ability at discharge (OR = 0.234 [0.127–0.432], p<0.001).

Fig 1 shows an odds ratio representation on early mortality of the mentioned significant variables.

Fig 1. Univariate risk representation of the studied variables showing statistical significance.

Fig 1

Blue: biodemographic variables; Red: fracture-related variables; Green: preoperative variables; Orange: postoperative variables; Grey: in-hospital stay derived variables.

At this stage within the study, we split the study population in half, by automatic randomization. It took 463 patients for multivariate risk assessment of selected preventable variables, and we validated the results for the 460 patients left. We could determinate a predictive model (S2 Table) that could explain 96.0% of non-early dying patients (sensitivity), and 60.7% of early dying patients (specificity), showing an AUC of 0.863 (Table 2, Fig 2).

Table 2. Sensibility and specificity of the multivariate model on each stage of development.
Study population 1 n = 463 Study population 2 n = 460 Complete study population
Sensitivity 98.9% 95.2% 96.0%
Specificity 52.0% 36.4% 60.7%
Fig 2. ROC curves for the developed predictive model on early mortality after hip fracture surgery, on each stage of development.

Fig 2

AUC: Area under the curve; CI: Confidence interval.

The prediction equation for the developed model is as follows:

Prediction=11+e-SCORE

Table 3 enables the score calculation for the prediction equation application. The mathematical expression would be as follows:

SCORE=-3.931+1.479LAlbAD+1.629NUPO+0.893ACSPO+1.757AK+PO-0.906RnIPO+1.429RsIPO+2.568CIPO+2.710SPPO+23.228STPO-1.597WAPO

AD: at admission; PO: Postoperative. LAlb: Lower albumin (<3.5g/dl); WA: Walking ability; NU: nutritional supply requirement; ACS: Acute confusional syndrome; AK+: Hyperkalaemia; RnI: Renal Insufficiency; RsI: Respiratory insufficiency; CI: Cardiac insufficiency; SP: Sepsis; ST: Stroke.

Table 3. Score calculation for the 30-day mortality prediction after hip fracture surgery in patients over 65.
Timeline Variable Record SCORE
Hip fracture surgical management Yes -3.931
Upon hospital admission Serum albumin (g/dl) <3.5 +1.479
≥3.5 0
Early postoperative (before hospital discharge) Nutritional supply requirement Yes +1.629
No 0
Acute confusional syndrome Yes +0.893
No 0
Hyperkalaemia Yes +1.757
No 0
Renal Insufficiency (acute or flared-up) Yes -0.906
No 0
Respiratory Insufficiency (acute or flared-up) Yes +1.429
No 0
Cardiac Insufficiency (acute or flared-up) Yes +2.568
No 0
Sepsis Yes +2.710
No 0
Stroke Yes +23.228
No 0
Walking ability Yes -1.597
No 0
SCORE Sum

Discussion

The current study analyses the influence of preoperative situation and comorbidities of older hip fracture patients on the 30-day mortality, but the main originality is that it also assesses potential early postoperative risk factors. We revealed that assessing certain postsurgical factors we could identify the frailest patients. While the postoperative risk factors assessed could be less modifiable, its identification itself represents a great advantage for the older hip fracture patients’ management. The influence of post-operative factors on early mortality has a logical basis, albeit so far they have not been identified or quantified before. This insight would support the in-hospital patient’s healthcare.

Mortality rates of hip fracture patients is a worldwide studied topic [3, 1420]. The 30-day mortality rate after hip fracture surgery could be an indirect indicator of the in-hospital quality of care [4]. The mortality rates we report, were lower than the mean mortality rates from the Spanish National Hip Fracture Registry (SNHFR) [21], and lower than other international studies, varying from 8.25% to 13.3% for the 30-day mortality [8, 11, 22]. These variations could reflect diverse factors, some would be inherent to each patient, like inner functional reserve, and others would be inherent to the healthcare process, as the time to surgery or the complications’ management. Factors understanding could be important to concentrate efforts to avoid that excess early mortality.

Biodemographic factors

Diverse studies have found a relationship between hip fracture mortality rate with age and gender [8, 23, 24], showing that the 30-day mortality rate after hip fracture is higher in men and oldest patients. We corroborate it, noting down the over 85 mean age of our population.

Fracture-related factors

We found significantly increased time to surgery in patients who early died, what is consistent with many other studies backing up the idea that early surgery could avoid the early mortality [4, 22, 2527]. However, it is difficult to consider the early surgery as a protective factor by itself, as this could not be achieved the more complex patients with poor previous medical conditions that may be playing as confounder factors. We consider maybe the risk factor previously assessed would be rather the late surgery than the early surgery. As our mean time to surgery never excess the five days, fewer patients underwent late surgery.

Preoperative clinical factors

We noticed that the lower lymphocyte count and albumin admission levels were associated with the 30-day mortality. It could be also related to those patients who will require nutritional supply and reveal the importance of the good nutritional status of older patients [28, 29].

We also noted a negative effect of the anticoagulant treatment. Patients suffering from chronic cardiac insufficiency, previous diagnosis of arrhythmia, or previous history of ischemic heart failure use to take anticoagulant treatment. The anticoagulant treatment always carries a higher time to surgery and could be a reason why we noted an increased time to surgery on early dying patients. Rutenberg et al. [30] also showed a relationship between anticoagulant treatment and increased time to surgery for hip fracture, but they did not associate the anticoagulant treatment with the one-year mortality. Nonetheless, other previous studies also showed an increased time to surgery but also decreased survival [3133].

Further, we recorded the Charlson comorbidity index, which showed a positive correlation with the 30-day mortality, as well as ASA grade. Both clinical scores assess high 30-day mortality in the worst clinical stated patients, what is consistent, and reveals the importance of the clinical status previous to hip fracture [24, 34].

Postoperative clinical factors

Regarding the surgical-derived complications, we found the hip dislocation as a relevant risk factor for early mortality. Some authors already noted that most hip dislocations occurred within the first month after surgery [3537]. Nonetheless, the incidence of this complication is varying from <1% to 3.5% [35, 37, 38]. Recently, Kishimoto et al. [39] pointed dislocation as a risk factor for long term survival after total hip arthroplasty, but only one case was a primary hip fracture. On the other hand, there are other works defeating no increase of mortality following a hip dislocation [35, 36]. Also, the prosthesis dislocation management may lead to bias for the results presented. Of the 407 patients who received hip arthroplasty in our study, only seven patients suffered a hip dislocation. Taking account of the low incidence of this complication in our study, we would consider a greater population to validate this finding.

On the medical postoperative complications, sepsis was the analysed risk factor showing the highest OR. Although sepsis incidence was slight, it is concordant that patient’s sepsis would carry a worse outcome. A similar upshot was revealed for the stroke [24]. The postoperative delirium is also a risk factor validated in this study, as previously pointed Mosk et al. [40] for later mortality.

We noted a higher incidence of sodium and potassium postoperative misbalance on the early mortality group, unexpected relevant risk factors not assessed before. It all raises the importance of metabolic monitoring for older patients undergoing hip fracture surgery. They could be also related to renal insufficiency, which also was assessed as a risk factor for early mortality, so those complications should be taken in high consideration, even with cardiac [41] and respiratory complications.

The ability to walk at discharge is a functional variable that seems to be a protective factor for the early mortality after hip fracture surgery, which agrees with its recent definition as a predictive factor for long-term survival [42].

Most studies already cited focused on pre-operative risk factors to assess the early mortality after hip fracture surgery, but we should consider the whole in-hospital process, including the immediate postoperative management, so it will significantly affect the patient’s outcome. We developed a novel early mortality prediction model, in which we only included preventable variables. Preventable variables were defined as those variables that are not inherent to the patient, but physicians could modify and take into consideration in order to prevent or motivate. Our model has a 96.0% sensitivity and 60.7% specificity, and AUC of 0.863, which validates it for further consideration on larger populations. It would allow us to early detect the frailest patients who underwent hip fracture surgery so we could assess an earlier follow-up to prevent early mortality.

There are other recently developed models assessing early mortality after hip fracture. Karres et al. [11] evaluated six different predictive models, some of them extensively used (as NHFS or O-Possum), and none of them showed excellent discrimination, as their AUC always were less than 0.8. The most recently published early mortality predictive model for hip fracture is the Brabant Hip Fracture Score [12], but no postoperative approach was assessed.

In conclusion, we found significant preoperative risk factors for early mortality after hip fracture, but the postoperative risk factors revealed a higher impact on the patient’s outcome at 30-days. In this sense, it is necessary to focus our efforts to decrease the postoperative complications rate on those patients in order to avoid the early mortality.

While the postoperative risk factors assessed could be less modifiable, its identification itself represents a great advantage for the older hip fracture patients’ management. This insight would support the in-hospital patient’s healthcare.

Besides our discussion, the study has some limitations as we studied single-center operated patients. Our upshot would be better considering a greater population.

Supporting information

S1 Table. Complete analysed descriptive data for all preoperative and postoperative factors analysed in the study population, and its comparison between the 30-day mortality group and survival group.

(PDF)

S2 Table. Definition of parameters in the equation for the predictive model assessing the 30-day mortality of hip fracture patients.

(PDF)

Data Availability

There are both ethical and legal restrictions on sharing the original study datasets. The electronic health records data cannot be shared publicly because it consists of personal information from which it is difficult to guarantee de-identification (Law 03/2018 from Spanish Government - BOE-A-2018-16673). There is a possibility of deductive disclosure of participants and therefore full data access through a public repository. The original datasets could only be made available under a new data sharing agreement with which includes: 1) commitment to using the data only for research purposes and not to identify any individual participant; 2) a commitment to securing the data using appropriate measures, and 3) a commitment to destroy or return the data after analyses are complete. For more information on data availability restrictions you can contact the ethics committee local IRB CEIm Area de Salud de Salamanca at comite.etico.husa@saludcastillayleon.es. Requests can be made to the corresponding author, who will connect the request to designated IRB representatives, and eventually send the information.

Funding Statement

The authors received no specific funding for this work.

References

  • 1.Kristensen PK, Thillemann TM, Søballe K, Johnsen SP. Can improved quality of care explain the success of orthogeriatric units? A population-based cohort study. Age Ageing. 2016;45: 66–71. 10.1093/ageing/afv155 [DOI] [PubMed] [Google Scholar]
  • 2.Giannoudis V, Panteli M, Giannoudis P V. Management of polytrauma patients in the UK: Is there a ‘weekend effect’? Injury. 2016;47: 2385–2390. 10.1016/j.injury.2016.10.007 [DOI] [PubMed] [Google Scholar]
  • 3.Katsoulis M, Benetou V, Karapetyan T, Feskanich D, Grodstein F, Pettersson-Kymmer U, et al. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med. 2017;281: 300–310. 10.1111/joim.12586 [DOI] [PubMed] [Google Scholar]
  • 4.Khan MA, Hossain FS, Ahmed I, Muthukumar N, Mohsen A. Predictors of early mortality after hip fracture surgery. Int Orthop. 2013;37: 2119–2124. 10.1007/s00264-013-2068-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Forni C, Gazineo D, D’Alessandro F, Fiorani A, Morri M, Sabattini T, et al. Predictive factors for thirty day mortality in geriatric patients with hip fractures: a prospective study. Int Orthop. 2019;43: 275–281. 10.1007/s00264-018-4057-x [DOI] [PubMed] [Google Scholar]
  • 6.Sheikh HQ, Hossain FS, Aqil A, Akinbamijo B, Mushtaq V, Kapoor H. A Comprehensive Analysis of the Causes and Predictors of 30-Day Mortality Following Hip Fracture Surgery. Clin Orthop Surg. 2017;9: 10–18. 10.4055/cios.2017.9.1.10 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Nijmeijer WS, Folbert EC, Vermeer M, Slaets JP, Hegeman JH. Prediction of early mortality following hip fracture surgery in frail elderly: The Almelo Hip Fracture Score (AHFS). Injury. 2016;47: 2138–2143. 10.1016/j.injury.2016.07.022 [DOI] [PubMed] [Google Scholar]
  • 8.Hu F, Jiang C, Shen J, Tang P, Wang Y. Preoperative predictors for mortality following hip fracture surgery: A systematic review and meta-analysis. Inj Int J Care Inj. 2012;43: 676–685. 10.1016/j.injury.2011.05.017 [DOI] [PubMed] [Google Scholar]
  • 9.Nikkel LE, Kates SL, Schreck M, Maceroli M, Mahmood B, Elfar JC. Length of hospital stay after hip fracture and risk of early mortality after discharge in New York state: retrospective cohort study. BMJ. 2015;351: h6246 10.1136/bmj.h6246 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Yong E-L, Ganesan G, Kramer MS, Howe Sen T, Koh JSB, Thu WP, et al. Risk Factors and Trends Associated With Mortality Among Adults With Hip Fracture in Singapore. JAMA Netw Open. 2020;3: e1919706 10.1001/jamanetworkopen.2019.19706 [DOI] [PubMed] [Google Scholar]
  • 11.Karres J, Heesakkers NA, Ultee JM, Vrouenraets BC. Predicting 30-day mortality following hip fracture surgery: Evaluation of six risk prediction models. Injury. 2015;46: 371–377. 10.1016/j.injury.2014.11.004 [DOI] [PubMed] [Google Scholar]
  • 12.van de Ree CL, Gosens T, van der Veen AH, Oosterbos CJ, Heymans MW, de Jongh MA. Development and validation of the Brabant Hip Fracture Score for 30-day and 1-year mortality. Hip Int. 2020;30: 354–362. 10.1177/1120700019836962 [DOI] [PubMed] [Google Scholar]
  • 13.Maxwell BG, Spitz W, Porter J. Association of Increasing Use of Spinal Anesthesia in Hip Fracture Repair With Treating an Aging Patient Population. JAMA Surg. 2020;155: 167 10.1001/jamasurg.2019.4471 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Empana J-P, Dargent-Molina P, Breart G, EPIDOS Group. Effect of Hip Fracture on Mortality in Elderly Women: The EPIDOS Prospective Study. J Am Geriatr Soc. 2004;52: 685–690. 10.1111/j.1532-5415.2004.52203.x [DOI] [PubMed] [Google Scholar]
  • 15.Kanis JA, Oden A, Johnell O, De Laet C, Jonsson B, Oglesby AK. The components of excess mortality after hip fracture. Bone. 2003;32: 468–473. 10.1016/s8756-3282(03)00061-9 [DOI] [PubMed] [Google Scholar]
  • 16.Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, et al. Meta-analysis: Excess Mortality After Hip Fracture Among Older Women and Men. Ann Intern Med. 2010;152: 380 10.7326/0003-4819-152-6-201003160-00008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Grønskag AB, Romundstad P, Forsmo S, Langhammer A, Schei B. Excess mortality after hip fracture among elderly women in Norway. Osteoporos Int. 2012;23: 1807–1811. 10.1007/s00198-011-1811-y [DOI] [PubMed] [Google Scholar]
  • 18.Farahmand BY, Michaëlsson K, Ahlbom A, Ljunghall S, Baron JA, Swedish Hip Fracture Study Group. Survival after hip fracture. Osteoporos Int. 2005;16: 1583–1590. 10.1007/s00198-005-2024-z [DOI] [PubMed] [Google Scholar]
  • 19.Richmond J, Aharonoff GB, Zuckerman JD, Koval KJ. Mortality risk after hip fracture. J Orthop Trauma. 2003;17: 53–6. 10.1097/00005131-200301000-00008 [DOI] [PubMed] [Google Scholar]
  • 20.Menéndez-Colino R, Alarcon T, Gotor P, Queipo R, Ramírez-Martín R, Otero A, et al. Baseline and pre-operative 1-year mortality risk factors in a cohort of 509 hip fracture patients consecutively admitted to a co-managed orthogeriatric unit (FONDA Cohort). Injury. 2018;49: 656–661. 10.1016/j.injury.2018.01.003 [DOI] [PubMed] [Google Scholar]
  • 21.Ojeda-Thies C, Sáez-López P, Currie CT, Tarazona-Santalbina FJ, Alarcón T, Muñoz-Pascual A, et al. Spanish National Hip Fracture Registry (RNFC): analysis of its first annual report and international comparison with other established registries. Osteoporos Int. 2019;30: 1243–1254. 10.1007/s00198-019-04939-2 [DOI] [PubMed] [Google Scholar]
  • 22.Pincus D, Ravi B, Wasserstein D, Huang A, Paterson JM, Nathens AB, et al. Association Between Wait Time and 30-Day Mortality in Adults Undergoing Hip Fracture Surgery. JAMA. 2017;318: 1994 10.1001/jama.2017.17606 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Liu Y, Wang Z, Xiao W. Risk factors for mortality in elderly patients with hip fractures: a meta-analysis of 18 studies. Aging Clin Exp Res. 2018;30: 323–330. 10.1007/s40520-017-0789-5 [DOI] [PubMed] [Google Scholar]
  • 24.Durand WM, Goodman AD, Johnson JP, Daniels AH. Assessment of 30-day mortality and complication rates associated with extended deep vein thrombosis prophylaxis following hip fracture surgery. Injury. 2018;49: 1141–1148. 10.1016/j.injury.2018.03.019 [DOI] [PubMed] [Google Scholar]
  • 25.Beaupre LA, Khong H, Smith C, Kang S, Evens L, Jaiswal PK, et al. The impact of time to surgery after hip fracture on mortality at 30- and 90-days: Does a single benchmark apply to all? Injury. 2019;50: 950–955. 10.1016/j.injury.2019.03.031 [DOI] [PubMed] [Google Scholar]
  • 26.Khan SK, Kalra S, Khanna A, Thiruvengada MM, Parker MJ. Timing of surgery for hip fractures: A systematic review of 52 published studies involving 291,413 patients. Injury. 2009;40: 692–697. 10.1016/j.injury.2009.01.010 [DOI] [PubMed] [Google Scholar]
  • 27.Lewis PM, Waddell JP. When is the ideal time to operate on a patient with a fracture of the hip? Bone Joint J. 2016;98-B: 1573–1581. 10.1302/0301-620X.98B12.BJJ-2016-0362.R2 [DOI] [PubMed] [Google Scholar]
  • 28.Bohl DD, Shen MR, Hannon CP, Fillingham YA, Darrith B, Della Valle CJ. Serum Albumin Predicts Survival and Postoperative Course Following Surgery for Geriatric Hip Fracture. J Bone Joint Surg Am. 2017;99: 2110–2118. 10.2106/JBJS.16.01620 [DOI] [PubMed] [Google Scholar]
  • 29.Wilson JM, Lunati MP, Grabel ZJ, Staley CA, Schwartz AM, Schenker ML. Hypoalbuminemia Is an Independent Risk Factor for 30-Day Mortality, Postoperative Complications, Readmission, and Reoperation in the Operative Lower Extremity Orthopaedic Trauma Patient. J Orthop Trauma. 2019;33: 284–291. 10.1097/BOT.0000000000001448 [DOI] [PubMed] [Google Scholar]
  • 30.Frenkel Rutenberg T, Velkes S, Vitenberg M, Leader A, Halavy Y, Raanani P, et al. Morbidity and mortality after fragility hip fracture surgery in patients receiving vitamin K antagonists and direct oral anticoagulants. Thromb Res. 2018;166: 106–112. 10.1016/j.thromres.2018.04.022 [DOI] [PubMed] [Google Scholar]
  • 31.Novoa-Parra CD, Hurtado-Cerezo J, Morales-Rodríguez J, Sanjuan-Cerveró R, Rodrigo-Pérez JL, Lizaur-Utrilla A. Factores predictivos de la mortalidad al año en pacientes mayores de 80 años intervenidos de fractura del cuello femoral. Rev Esp Cir Ortop Traumatol. 2019;63: 202–208. [DOI] [PubMed] [Google Scholar]
  • 32.Lawrence JE, Fountain DM, Cundall-Curry DJ, Carrothers AD. Do Patients Taking Warfarin Experience Delays to Theatre, Longer Hospital Stay, and Poorer Survival After Hip Fracture? Clin Orthop Relat Res. 2017;475: 273–279. 10.1007/s11999-016-5056-0 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.López S, da Casa C, Pablos-Hernández C, Pescador D, Díaz-Álvarez A, Asensio N, et al. The impact of antithrombotic therapy on surgical delay and 2-year mortality in older patients with hip fracture: a prospective observational study. Eur Geriatr Med. 2020;11: 555–561. 10.1007/s41999-020-00293-3 [DOI] [PubMed] [Google Scholar]
  • 34.Smith T, Pelpola K, Ball M, Ong A, Myint PK. Pre-operative indicators for mortality following hip fracture surgery: a systematic review and meta-analysis. Age Ageing. 2014;43: 464–471. 10.1093/ageing/afu065 [DOI] [PubMed] [Google Scholar]
  • 35.Gill JR, Kiliyanpilakkill B, Parker MJ. Management and outcome of the dislocated hip hemiarthroplasty. Bone Joint J. 2018;100-B: 1618–1625. 10.1302/0301-620X.100B12.BJJ-2018-0281.R1 [DOI] [PubMed] [Google Scholar]
  • 36.Salem K, Shannak O, Scammell B, Moran C. Predictors and outcomes of treatment in hip hemiarthroplasty dislocation. Ann R Coll Surg Engl. 2014;96: 446–451. 10.1308/003588414X13946184903045 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Jones C, Briffa N, Jacob J, Hargrove R. The Dislocated Hip Hemiarthroplasty: Current Concepts of Etiological factors and Management. Open Orthop J. 2017;11: 1200–1212. 10.2174/1874325001711011200 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Hansson S, Bülow E, Garland A, Kärrholm J, Rogmark C. More hip complications after total hip arthroplasty than after hemi-arthroplasty as hip fracture treatment: analysis of 5,815 matched pairs in the Swedish Hip Arthroplasty Register. Acta Orthop. 2020;91: 133–138. 10.1080/17453674.2019.1690339 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39.Kishimoto Y, Kato Y, Kishi T, Takahashi T, Kuranobu K. Dislocation is a Leading Cause of Decreased Survival Rate in Primary Total Hip Arthroplasty Performed by Low-Volume Surgeons: Long-Term Retrospective Cohort Study. J Arthroplasty. 2020;Article in: S0883-5403(20)30605–7. 10.1016/j.arth.2020.05.064 [DOI] [PubMed] [Google Scholar]
  • 40.Mosk C, Mus M, Vroemen J, van der Ploeg T, Vos D, Elmans L, et al. Dementia and delirium, the outcomes in elderly hip fracture patients. Clin Interv Aging. 2017;12: 421–430. 10.2147/CIA.S115945 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Lee R, Lee D, Gowda NB, Probasco W V, Ibrahim G, Falk DP, et al. Surgical complications associated with congestive heart failure in elderly patients following primary hip hemiarthroplasty for femoral neck fractures. Eur J Orthop Surg Traumatol. 2019;Epub ahead. 10.1007/s00590-019-02438-y [DOI] [PubMed] [Google Scholar]
  • 42.Iosifidis M, Iliopoulos E, Panagiotou A, Apostolidis K, Traios S, Giantsis G. Walking ability before and after a hip fracture in elderly predict greater long-term survivorship. J Orthop Sci. 2016;21: 48–52. 10.1016/j.jos.2015.09.009 [DOI] [PubMed] [Google Scholar]

Decision Letter 0

Osama Farouk

13 Jan 2021

PONE-D-20-36438

Early mortality after hip fracture surgery: influence of postoperative factors

PLOS ONE

Dear Dr. da Casa,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

Please submit your revised manuscript by Feb 20 2021 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols

We look forward to receiving your revised manuscript.

Kind regards,

Osama Farouk

Academic Editor

PLOS ONE

Journal Requirements:

When submitting your revision, we need you to address these additional requirements.

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. We note that you have indicated that data from this study are available upon request. PLOS only allows data to be available upon request if there are legal or ethical restrictions on sharing data publicly. For information on unacceptable data access restrictions, please see http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions.

In your revised cover letter, please address the following prompts:

a) If there are ethical or legal restrictions on sharing a de-identified data set, please explain them in detail (e.g., data contain potentially identifying or sensitive patient information) and who has imposed them (e.g., an ethics committee). Please also provide contact information for a data access committee, ethics committee, or other institutional body to which data requests may be sent.

b) If there are no restrictions, please upload the minimal anonymized data set necessary to replicate your study findings as either Supporting Information files or to a stable, public repository and provide us with the relevant URLs, DOIs, or accession numbers. Please see http://www.bmj.com/content/340/bmj.c181.long for guidelines on how to de-identify and prepare clinical data for publication. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories.

We will update your Data Availability statement on your behalf to reflect the information you provide.

3. Your ethics statement should only appear in the Methods section of your manuscript. If your ethics statement is written in any section besides the Methods, please move it to the Methods section and delete it from any other section. Please ensure that your ethics statement is included in your manuscript, as the ethics statement entered into the online submission form will not be published alongside your manuscript.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear authors, i appreciate the work done in this manuscript and i hope that my comments will help further improvement.

Title: i believe that it is better to mention that it is a 30 days mortality instead of just mentioning "early mortality"

Abstract: statistical analysis details better to be removed form the abstract, line 30: the word study is repeated, in the aim define what is considered as "early mortality"

Keywords: should include 30 days or at least early postoperative.

Introduction: well prepared and informative. the aim need to be more clear, define the early mortality (define the time period) as recommended earlier for the abstract.

-Methods: i would like the authors to clearly explain the aim of the telephonic follow up, did they only ask regarding mortality only, did they collect any data leading to mortality, if the patient is still alive would, how did the authors collected the data in concern?

-i understand that the aim was to detect the 30 days mortality, however, i was wondering why the authors chose to only evaluate the mortality in this short period, will patient surviving this period be able to live longer?

Results: the comparisons are not clear, it is confusing.

-Table 1 need to be more clear: what did the authors mean by rural residence, as this may differ between countries?, what did they mean by institution living (was it a nursing facility?)

-for the biodemographic variables, the authors mentioned that men had a higher early mortality, however in table 1 they reported that the female gender early mortality was 54.5% of the whole mortality incidence. The authors mentioned higher mortality in the 90 years age group, higher that which other group??

-for the fracture related variables: it is a common sense that patients who had a delayed surgery to have a comorbidity, as the medical issues in these fragile patients are the main reason for surgery delay, not just the fracture type. It is difficult to consider early surgery as a protective factor by itself , as this could not be achieved in all patients with medical comorbidities, higher ASA, bad lab variables are playing as a confounder for this variable.

-for the preoperative clinical values: it is better to divide these into categories (clinical, lab,...)

-postoperative clinical values: considering the type of surgery the patient had in this category is wrong, the other important point is the relation of the early prothesis dislocation to the early mortality, the authors should indicate if these patients who were subjected to early dislocations were treated surgically and were subjected to anathesia or not, as the dislocation by itself is not the risk, however, the way of management of this dislocation posses the risk on the patient.

-the postoperative category: better to be divided into subheadings for more fluency.

-Figures should be more clear

-Page 10, line 190: the authors mentioned "at this stage", what is the stage they refereed to at this point.

-page 10, line 198: the formula mentioned, score=: where is the results of this score, or the numbers the reader should get when applying the same formula. The formula mentioned is unclear and confusing, should be explained in a more simple and reproducible way.

Discussion: well presented.

Reviewer #2: The Manuscript:

Early mortality after hip fracture surgery: influence of postoperative factors

describes the results from a prospective cohort study on patients suffering from proximal Femur fractures. The authors identified several Risk factors and calculated a Risk scor System with a significant prediction rate. Principially, this is a very important work and the data is worthy for publication. In respect to several other epidemiological studies, probably some clarifications/idscussions wopuld be helpfull: the authors describe a Overall mortality of 6%, which might be normal in the analysed collective 65-100 years; hence, it would be good to calculate the "excess mortality" of the collective to identify the effect; moreover, the significant correlation between Prolongation of surgery above 24 or 48 Hours is well known as a Surrogate Parameter for co-morbidities, especially, anti-coagulative therapy. Hence, the conclusion to operate These patients as earloy as possible using potential dangerous pro-coagulative medication, such as PBSB, should be discussed critically according to quantitative Risk factor Adjustment. Besdie that, a good paper and congratultions

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2021 Feb 16;16(2):e0246963. doi: 10.1371/journal.pone.0246963.r002

Author response to Decision Letter 0


15 Jan 2021

30-day mortality after hip fracture surgery: influence of postoperative factors.

Response to reviwers

Reviewer #1: Dear authors, i appreciate the work done in this manuscript and i hope that my comments will help further improvement.

>Thank you very much. We hope that the arrangements you suggested and we made (further detailed) could improve the manuscript.

Title: i believe that it is better to mention that it is a 30 days mortality instead of just mentioning "early mortality"

>Actually we already had a talk about that topic and we agree with you and have changed the term also in the title.

Abstract: statistical analysis details better to be removed form the abstract, line 30: the word study is repeated, in the aim define what is considered as "early mortality"

>Thank you. We have corrected the erratum in text and specified “30-day mortality”.

Keywords: should include 30 days or at least early postoperative.

>Thank you, we have now included both terms as key words.

Introduction: well prepared and informative. the aim need to be more clear, define the early mortality (define the time period) as recommended earlier for the abstract.

>Thank you for your comment. We have enlarged line 68 “The early mortality rate, defined as 30-day mortality rate after hospital discharge, has been considered as an indirect indicator of the quality of care”, in order to be more informative and clear. We have also changed the term “early mortality” to “30-day mortality” in the purpose description.

-Methods: i would like the authors to clearly explain the aim of the telephonic follow up, did they only ask regarding mortality only, did they collect any data leading to mortality, if the patient is still alive would, how did the authors collected the data in concern?

>Indeed, at the 30-day follow-up some patients were invited to hospital visit and underwent a whole physical medical evaluation, but oldest or frailest patients were contacted by phone. At the telephonic follow-up we asked for the patient status, not only regarding mortality, but we only recorded mortality status, as it was the actual aim of the study data collection. We have no records on cause of mortality and, as we only designed a prospective study with 30-day follow-up after hospital discharge, we have no further record for longer mortality.

We noted the day for the follow-up contact (at least 30-days after hospital discharge) and the dead/alive status of each patient. If the patient was already dead, we also noted the date for death, but no further records on leading cause for mortality were noted down.

See lines 96-97 “We performed on-site or telephonic 30-day follow up, noting down records for mortality.”

-i understand that the aim was to detect the 30 days mortality, however, i was wondering why the authors chose to only evaluate the mortality in this short period, will patient surviving this period be able to live longer?

>Thank you for the notation. We have already pointed it out on our previous response. Of course, patients could life much longer, indeed we have already published other studies designed with longer follow up [1]. For the present study, we aimed to note down the risk factors for the early mortality, what could be considered as indirect indicator of the healthcare quality during the hospital stay. The end-point of our work would be to allocate hospital resources according to patients’ requirements. Longer mortality could also be related to the patient inherent status and we should bear in mind that the mean age of the studied population is already over 85.

1. da Casa C, Pablos-Hernández C, González-Ramírez A, et al (2019) Geriatric scores can predict long-term survival rate after hip fracture surgery. BMC Geriatr 19:205. https://doi.org/10.1186/s12877-019-1223-y

Results: the comparisons are not clear, it is confusing.

>Thank you for the comment. We apologize for it. We have tried our best to improve results descriptions according to your recommendations. We have also changed Table 1 lines presentation (according to PLos One guidelines) to ease the statistical comparisons understanding.

-Table 1 need to be more clear: what did the authors mean by rural residence, as this may differ between countries?, what did they mean by institution living (was it a nursing facility?)

>Thank you again for your comment. We have specified both terms in Table 1 in order to be more clear and precise. Rural residence was considered for patients living in small municipalities composed by less than 12,500 inhabitants. They use to have a more active daily life that we though could be related to patient outcome. As you pointed, we meant patients living at a nursing facility when noting down “institution-living”; it was just a language misunderstanding since in Spain nursing homes are not the only ones in attending this type of institution-living patients (but also religious facilities in example).

-for the biodemographic variables, the authors mentioned that men had a higher early mortality, however in table 1 they reported that the female gender early mortality was 54.5% of the whole mortality incidence. The authors mentioned higher mortality in the 90 years age group, higher that which other group??

>Thank you for your comment. As you pointed, women represented over 50% of early deaths recorded, but we should bear in mind that women already represented over 70% of the whole study population. From another point of view, men were around 30% of the whole population, and around 50% of the early dying population. It all showed that a man being surgically treated for a hip fracture has increased probability for early dying than a woman. Results in Table 1 were presented for female gender as it is the bigger group of patients. In lines 128-130 we have tried to explain it “We noted a significantly higher rate of men in the early-mortality group […] than the original population gender distribution”.

We noted a “higher rate of patients over age 90 in the early mortality group”; higher than patients under 90 years’ age group. We apologize if it was not enough clearly exposed.

-for the fracture related variables: it is a common sense that patients who had a delayed surgery to have a comorbidity, as the medical issues in these fragile patients are the main reason for surgery delay, not just the fracture type. It is difficult to consider early surgery as a protective factor by itself, as this could not be achieved in all patients with medical comorbidities, higher ASA, bad lab variables are playing as a confounder for this variable.

>Thank you again for your comment. We agree with you, as we already pointed in our discussion: “We consider maybe the risk factor assessed would be rather the late surgery than the early surgery.”

We have no further included the early surgery on the statistical model developed, due to, as you pointed, it could not be modifiable in the more complex patients. We hope you have no objection that we have incorporated your comment with slight modifications to the revised version of our manuscript.

-for the preoperative clinical values: it is better to divide these into categories (clinical, lab,...)

>Thank you for the notation. We have arranged it.

-postoperative clinical values: considering the type of surgery the patient had in this category is wrong, the other important point is the relation of the early prothesis dislocation to the early mortality, the authors should indicate if these patients who were subjected to early dislocations were treated surgically and were subjected to anathesia or not, as the dislocation by itself is not the risk, however, the way of management of this dislocation posses the risk on the patient.

>Thank you for your comment. We considered the type of surgery as a “fracture-related” factor (see lines 135-136), but the early prosthesis dislocation was considered as a postoperative clinical factor, only noted for arthroplasty-treated patients (osteosynthesis-based patients could not undergo prosthesis dislocation and were excluded for statistical analysis). We acknowledge your contribution regarding the dislocation management. Unfortunately, we have no records on it, and the study stood only for the dislocation event itself. Again, we should bear in mind that the incidence of prosthesis dislocation is low, and, although we studied a large population, it is still small to be able to split the prosthesis dislocation management and study its consequences. We have annotated your contribution on the revised manuscript (line 298).

-the postoperative category: better to be divided into subheadings for more fluency.

>Thank you for the notation. We have tried to arranged it by adding two subheadings and splitting paragraphs in order to expose it easier for lectors.

-Figures should be more clear

>Thank you for the comment. We have improved the images quality and we hope they would be now clearer for publication.

-Page 10, line 190: the authors mentioned "at this stage", what is the stage they refereed to at this point.

>Thank for the comment. Probably we just omit what we meant. It was just a conjunction for expressing the study stage. We firstly made the univariate analysis and then developed the predictive model.

-page 10, line 198: the formula mentioned, score=: where is the results of this score, or the numbers the reader should get when applying the same formula. The formula mentioned is unclear and confusing, should be explained in a more simple and reproducible way.

>Thank you for the comment. We have tried our best to clarify the prediction calculation. We have translated the complex mathematical formulae to a simpler and useful table (see Table 3) in order to obtain the score. We acknowledge your contribution and we believe that with the table format would be easier to apply the prediction model here presented.

Discussion: well presented.

>Thank you very much. We appreciate your time and effort and we believe your notations have help us to improve our manuscript.

Reviewer #2:

The Manuscript: Early mortality after hip fracture surgery: influence of postoperative factors

describes the results from a prospective cohort study on patients suffering from proximal Femur fractures. The authors identified several Risk factors and calculated a Risk scor System with a significant prediction rate. Principially, this is a very important work and the data is worthy for publication.

>Thank you very much for your appreciation.

In respect to several other epidemiological studies, probably some clarifications/idscussions wopuld be helpfull: the authors describe a Overall mortality of 6%, which might be normal in the analysed collective 65-100 years; hence, it would be good to calculate the "excess mortality" of the collective to identify the effect;

>Thank you for your comment. We really appreciate your suggestion, but we certainly don't have the data nor the necessary tools to be able to carry out the discussion you are suggesting. It would be probably a great complementary study that we will further try to perform. Unfortunately, at the moment, we are unable to present the requested calculation.

moreover, the significant correlation between Prolongation of surgery above 24 or 48 Hours is well known as a Surrogate Parameter for co-morbidities, especially, anti-coagulative therapy. Hence, the conclusion to operate These patients as earloy as possible using potential dangerous pro-coagulative medication, such as PBSB, should be discussed critically according to quantitative Risk factor Adjustment.

>Thank you for your notation. We agree with you and we have tried to include this statement on the discussion (Lines 166-168). We have no records on the use of pro-coagulative medication in this study population, but we will bear it in mind for further studies. Nevertheless, we did not to include the early surgery on the prediction model developed as it could not be modifiable in the more complex patients.

Besdie that, a good paper and congratulations

>Thank you very much again for your appreciation. We hope that all other arrangements we made could improve our manuscript.

Attachment

Submitted filename: Response to Reviewers.docx

Decision Letter 1

Osama Farouk

29 Jan 2021

30-day mortality after hip fracture surgery: influence of postoperative factors

PONE-D-20-36438R1

Dear Dr. da Casa,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Osama Farouk

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear authors, i was very delighted to review your revised version of the manuscript, thanks for responding to the recommendations and suggestions. Wish you all the best.

Reviewer #2: Although the data of excess mortality could not be provided, I think this is an improtant piece of work for the scientific community and should be published

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Ahmed Adel Khalifa, MD, FRCS, MSc

Reviewer #2: No

Acceptance letter

Osama Farouk

2 Feb 2021

PONE-D-20-36438R1

30-day mortality after hip fracture surgery: influence of postoperative factors.

Dear Dr. da Casa:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Osama Farouk

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Table. Complete analysed descriptive data for all preoperative and postoperative factors analysed in the study population, and its comparison between the 30-day mortality group and survival group.

    (PDF)

    S2 Table. Definition of parameters in the equation for the predictive model assessing the 30-day mortality of hip fracture patients.

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers.docx

    Data Availability Statement

    There are both ethical and legal restrictions on sharing the original study datasets. The electronic health records data cannot be shared publicly because it consists of personal information from which it is difficult to guarantee de-identification (Law 03/2018 from Spanish Government - BOE-A-2018-16673). There is a possibility of deductive disclosure of participants and therefore full data access through a public repository. The original datasets could only be made available under a new data sharing agreement with which includes: 1) commitment to using the data only for research purposes and not to identify any individual participant; 2) a commitment to securing the data using appropriate measures, and 3) a commitment to destroy or return the data after analyses are complete. For more information on data availability restrictions you can contact the ethics committee local IRB CEIm Area de Salud de Salamanca at comite.etico.husa@saludcastillayleon.es. Requests can be made to the corresponding author, who will connect the request to designated IRB representatives, and eventually send the information.


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES